← Leaderboards
David J. Kwiatkowski
Brigham And Women'S Hospital
$31,996,627
Attributed
$32,943,115
Total exposure
27
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$64,741,308 · 28
By mechanism
P01$52,259,223 · 16
R01$5,416,546 · 4
R37$2,529,897 · 1
U01$2,159,097 · 2
RC1$996,026 · 1
R21$896,951 · 2
Top collaborators
- Toni Choueiri2 shared
- Elizabeth P Henske2 shared
- Guru Sonpavde1 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Elizabeth P Henske$25,563,270
- Chin-Lee Wu$1,488,018
Others in their field
Top investigators on “Pathogenesis”
- Jeffrey P Krischer · University Of South Florida$473,867,135
- Constance Ann Benson · University Of California, San Diego$309,631,408
- Daniel R Kuritzkes · Brigham And Women'S Hospital$212,627,101
- Richard K. Wilson · Washington University$203,917,615
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$198,007,440
- Carol Nesel · Westat$147,274,423
Research focus
PathogenesisMalignant NeoplasmsSyndromeHamartomaTsc2 GeneMolecularGenesGeneticTsc1 GenePathway InteractionsTumorMutationEventProgramsCellsGrowthPten GeneTuberous SclerosisTumor Suppressor GenesResponseSignal TransductionCell LineResearch PersonnelIn Vivo
Grant awards (133)
Molecular Pathogenesis of the Hamartoma Syndromes$2,056,023
P01 · FY2025 · CA · contact PI
Project 3: Identifying transcriptional driver genes and targeting transcription in TSC$776,636
P01 · FY2025 · CA · contact PI
Project 2: Identifying Metabolic vulnerabilities and targets in cancers with mutations in hamartoma genes$552,000
P01 · FY2025 · CA · contact PI
Project 1: Identifying new therapeutic avenues to selectively target tumors with uncontrolled mTORC1 activation$493,468
P01 · FY2025 · CA · contact PI
Core B: Mass Spectrometry, proteomics, metabolmics and lipidomics$149,913
P01 · FY2025 · CA · contact PI
Core A: Administration$84,006
P01 · FY2025 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,956,770
P01 · FY2024 · CA · contact PI
Project 3: Identifying transcriptional driver genes and targeting transcription in TSC$741,557
P01 · FY2024 · CA · contact PI
Project 2: Identifying Metabolic vulnerabilities and targets in cancers with mutations in hamartoma genes$524,400
P01 · FY2024 · CA · contact PI
Project 1: Identifying new therapeutic avenues to selectively target tumors with uncontrolled mTORC1 activation$468,591
P01 · FY2024 · CA · contact PI
Genetics of LAM$440,661
R01 · FY2024 · HL · contact PI
Core B: Mass Spectrometry, proteomics, metabolmics and lipidomics$142,417
P01 · FY2024 · CA · contact PI
Core A: Administration$79,805
P01 · FY2024 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$2,168,446
P01 · FY2023 · CA · contact PI
Project 3: Identifying transcriptional driver genes and targeting transcription in TSC$792,435
P01 · FY2023 · CA · contact PI
Project 2: Identifying Metabolic vulnerabilities and targets in cancers with mutations in hamartoma genes$591,500
P01 · FY2023 · CA · contact PI
Project 1: Identifying new therapeutic avenues to selectively target tumors with uncontrolled mTORC1 activation$530,842
P01 · FY2023 · CA · contact PI
Genetics of LAM$449,654
R01 · FY2023 · HL · contact PI
Core B: Mass Spectrometry, proteomics, metabolmics and lipidomics$169,663
P01 · FY2023 · CA · contact PI
Core A: Administration$84,006
P01 · FY2023 · CA · contact PI
Program 09 Cancer Genetics$43,241
P30 · FY2023 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,726,137
P01 · FY2022 · CA · contact PI
Project 2: Identifying Metabolic vulnerabilities and targets in cancers with mutations in hamartoma genes$533,326
P01 · FY2022 · CA · contact PI
Project 1: Identifying new therapeutic avenues to selectively target tumors with uncontrolled mTORC1 activation$484,846
P01 · FY2022 · CA · contact PI
Project 3: Identifying transcriptional driver genes and targeting transcription in TSC$482,742
P01 · FY2022 · CA · contact PI
Genetics of LAM$449,654
R01 · FY2022 · HL · contact PI
Core A: Administration$54,631
P01 · FY2022 · CA · contact PI
Program 09 Cancer Genetics$43,239
P30 · FY2022 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,761,363
P01 · FY2021 · CA · contact PI
Project 2: Identifying Metabolic vulnerabilities and targets in cancers with mutations in hamartoma genes$544,210
P01 · FY2021 · CA · contact PI
Project 1: Identifying new therapeutic avenues to selectively target tumors with uncontrolled mTORC1 activation$494,739
P01 · FY2021 · CA · contact PI
Project 3: Identifying transcriptional driver genes and targeting transcription in TSC$492,594
P01 · FY2021 · CA · contact PI
Integrative molecular dissection of acquired resistance to PD1/PD-L1 blockade in localized and metastatic urothelial carcinoma$476,334
R21 · FY2021 · CA
Genetics of LAM$469,404
R01 · FY2021 · HL · contact PI
Program 9: Cancer Genetics$74,408
P30 · FY2021 · CA · contact PI
Core A: Administration$55,746
P01 · FY2021 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,761,364
P01 · FY2020 · CA · contact PI
Project 2: Identifying Metabolic vulnerabilities and targets in cancers with mutations in hamartoma genes$544,210
P01 · FY2020 · CA · contact PI
Project 1: Identifying new therapeutic avenues to selectively target tumors with uncontrolled mTORC1 activation$494,740
P01 · FY2020 · CA · contact PI
Project 3: Identifying transcriptional driver genes and targeting transcription in TSC$492,594
P01 · FY2020 · CA · contact PI
Program 9: Cancer Genetics$74,295
P30 · FY2020 · CA · contact PI
Core A: Administration$55,746
P01 · FY2020 · CA · contact PI
Program 9: Cancer Genetics$2,948
P30 · FY2020 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,710,394
P01 · FY2019 · CA · contact PI
Project 2: Identifying Metabolic vulnerabilities and targets in cancers with mutations in hamartoma genes$577,690
P01 · FY2019 · CA · contact PI
Project 1: Identifying new therapeutic avenues to selectively target tumors with uncontrolled mTORC1 activation$528,218
P01 · FY2019 · CA · contact PI
Project 3: Identifying transcriptional driver genes and targeting transcription in TSC$333,541
P01 · FY2019 · CA · contact PI
Program 9: Cancer Genetics$72,663
P30 · FY2019 · CA · contact PI
Core A: Administration$64,622
P01 · FY2019 · CA · contact PI
Program 9: Cancer Genetics$6,168
P30 · FY2019 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,897,687
P01 · FY2018 · CA · contact PI
Project 2: Identifying Metabolic vulnerabilities and targets in cancers with mutations in hamartoma genes$583,714
P01 · FY2018 · CA · contact PI
Project 1: Identifying new therapeutic avenues to selectively target tumors with uncontrolled mTORC1 activation$534,240
P01 · FY2018 · CA · contact PI
Project 3: Identifying transcriptional driver genes and targeting transcription in TSC$530,163
P01 · FY2018 · CA · contact PI
Program 9: Cancer Genetics$78,659
P30 · FY2018 · CA · contact PI
Core A: Administration$55,746
P01 · FY2018 · CA · contact PI
Program 9: Cancer Genetics$11,430
P30 · FY2018 · CA · contact PI
Program 9: Cancer Genetics$5,849
P30 · FY2018 · CA · contact PI
Program 9: Cancer Genetics$5,123
P30 · FY2018 · CA · contact PI
Program 9: Cancer Genetics$3,833
P30 · FY2018 · CA · contact PI
Program 9: Cancer Genetics$1,602
P30 · FY2018 · CA · contact PI
Program 9: Cancer Genetics$60,110
P30 · FY2017 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,781,629
P01 · FY2016 · CA · contact PI
Integrated analyses of cancers harboring STK11 vs. TSC1/2 vs. PTEN Loss$472,743
P01 · FY2016 · CA · contact PI
Genetic Predictors of Response to mTOR inhibitors in advanced Renal Cancer$191,321
R21 · FY2016 · CA
Administrative Core$30,582
P01 · FY2016 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,781,486
P01 · FY2015 · CA · contact PI
Integrated analyses of cancers harboring STK11 vs. TSC1/2 vs. PTEN Loss$475,087
P01 · FY2015 · CA · contact PI
Genetic Predictors of Response to mTOR inhibitors in advanced Renal Cancer$229,296
R21 · FY2015 · CA
Administrative Core$35,971
P01 · FY2015 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,727,206
P01 · FY2014 · CA · contact PI
Integrated analyses of cancers harboring STK11 vs. TSC1/2 vs. PTEN Loss$463,273
P01 · FY2014 · CA · contact PI
Administrative Core$28,427
P01 · FY2014 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,672,978
P01 · FY2013 · CA · contact PI
Integrated analyses of cancers harboring STK11 vs. TSC1/2 vs. PTEN Loss$441,384
P01 · FY2013 · CA · contact PI
Tuberous Sclerosis: Mutations and Murine Models$377,710
R37 · FY2013 · NS · contact PI
Administrative Core$32,935
P01 · FY2013 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,911,547
P01 · FY2012 · CA · contact PI
Integrated analyses of cancers harboring STK11 vs. TSC1/2 vs. PTEN Loss$540,360
P01 · FY2012 · CA · contact PI
Tuberous Sclerosis: Mutations and Murine Models$398,672
R37 · FY2012 · NS · contact PI
Mouse Brain Models of Tuberous Sclerosis$298,424
P01 · FY2012 · NS · contact PI
Administrative Core$43,784
P01 · FY2012 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,558,264
P01 · FY2011 · CA · contact PI
Tuberous Sclerosis-Pathway and Pathogenesis$410,383
P01 · FY2011 · CA · contact PI
Tuberous Sclerosis: Mutations and Murine Models$404,201
R37 · FY2011 · NS · contact PI
Mouse Brain Models of Tuberous Sclerosis$305,344
P01 · FY2011 · NS · contact PI
Administrative Core$27,917
P01 · FY2011 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,612,774
P01 · FY2010 · CA · contact PI
The Lymphangioleiomyomatosis (LAM)Genome Atlas$496,038
RC1 · FY2010 · HL · contact PI
Tuberous Sclerosis-Pathway and Pathogenesis$424,499
P01 · FY2010 · CA · contact PI
Tuberous Sclerosis: Mutations and Murine Models$332,809
R37 · FY2010 · NS · contact PI
Mouse Brain Models of Tuberous Sclerosis$305,345
P01 · FY2010 · NS · contact PI
Administrative Core$29,087
P01 · FY2010 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,602,198
P01 · FY2009 · CA · contact PI
The Lymphangioleiomyomatosis (LAM)Genome Atlas$499,988
RC1 · FY2009 · HL · contact PI
Tuberous Sclerosis-Pathway and Pathogenesis$433,144
P01 · FY2009 · CA · contact PI
Tuberous Sclerosis: Mutations and Murine Models$337,529
R37 · FY2009 · NS · contact PI
Mouse Brain Models of Tuberous Sclerosis$308,855
P01 · FY2009 · NS · contact PI
Administrative Core$28,788
P01 · FY2009 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,561,097
P01 · FY2008 · CA · contact PI
Tuberous Sclerosis-Pathway and Pathogenesis$430,816
P01 · FY2008 · CA · contact PI
Tuberous Sclerosis: Mutations and Murine Models$338,848
R37 · FY2008 · NS · contact PI
Mouse Brain Models of Tuberous Sclerosis$312,537
P01 · FY2008 · NS · contact PI
Administrative Core$28,809
P01 · FY2008 · CA · contact PI
Molecular Pathogenesis of the Hamartoma Syndromes$1,550,830
P01 · FY2007 · CA · contact PI
Tuberous Sclerosis-Pathway and Pathogenesis$405,156
P01 · FY2007 · CA · contact PI
Tuberous Sclerosis: Mutations and Murine Models$340,128
R37 · FY2007 · NS · contact PI
Administrative Core$28,083
P01 · FY2007 · CA · contact PI
Tuberous Sclerosis: Mutations and Murine Models$323,087
R01 · FY2006 · NS · contact PI
Preclinical Studies of Rapamycin for TSC Brain Disease$150,537
U01 · FY2006 · NS · contact PI
Tuberous Sclerosis: Mutations and Murine Models$332,676
R01 · FY2005 · NS
Preclinical Studies of Rapamycin for TSC Brain Disease$177,844
U01 · FY2005 · NS
Tuberous Sclerosis: Mutations and Murine Models$334,419
R01 · FY2004 · NS
Preclinical Studies of Rapamycin for TSC Brain Disease$172,664
U01 · FY2004 · NS
GENOTYPING CENTER FOR INNATE IMMUNITY PGA$81,950
U01 · FY2004 · HL
GENOTYPING CENTER FOR INNATE IMMUNITY PGA$478,234
U01 · FY2003 · HL
Tuberous Sclerosis: Mutations and Murine Models$336,095
R01 · FY2003 · NS
GELSOLIN: ROLES IN APOPTOSIS AND TUMOR DEVELOPMENT$301,399
R01 · FY2003 · HL
Tuberous Sclerosis: Mutations and Murine Models$50,000
R01 · FY2003 · NS
GENOTYPING CENTER FOR INNATE IMMUNITY PGA$362,596
U01 · FY2002 · HL
Tuberous Sclerosis: Mutations and Murine Models$336,716
R01 · FY2002 · NS
GELSOLIN: ROLES IN APOPTOSIS AND TUMOR DEVELOPMENT$301,399
R01 · FY2002 · HL
Tuberous Sclerosis: Mutations and Murine Models$20,000
R01 · FY2002 · NS
MURINE MODELS OF TSC1: MECHANISMS AND THERAPIES$0
P01 · FY2002 · NS
GENOTYPING CENTER FOR INNATE IMMUNITY PGA$433,530
U01 · FY2001 · HL
GELSOLIN: ROLES IN APOPTOSIS AND TUMOR DEVELOPMENT$301,399
R01 · FY2001 · HL
TUBEROUS SCLEROSIS--MUTATIONS AND MURINE MODELS$263,650
R01 · FY2001 · NS
MURINE MODELS OF TSC 1: MECHANISMS AND THERAPIES$98,963
R01 · FY2001 · NS
MURINE MODELS OF TSC1: MECHANISMS AND THERAPIES$0
P01 · FY2001 · NS
GENOTYPING CENTER FOR INNATE IMMUNITY PGA$301,742
U01 · FY2000 · HL
GELSOLIN--ROLES IN APOPTOSIS AND TUMOR DEVELOPMENT$301,399
R01 · FY2000 · HL
TUBEROUS SCLEROSIS--MUTATIONS AND MURINE MODELS$255,971
R01 · FY2000 · NS
TUBEROUS SCLEROSIS--MUTATIONS AND MURINE MODELS$50,000
R01 · FY2000 · NS